Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,312 public trials 521 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Completed

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

NCT04105010

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Yale Cancer Center New Haven, Connecticut, United States
  • Winship Cancer Institute Atlanta, Georgia, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 50 locations
View Trial Details
Completed

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT03734016

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +16 more
Locations
  • Carti Cancer Center Little Rock, Arkansas, United States
  • David Geffen School of Medicine At UCLA Los Angeles, California, United States
  • Rocky Mountain Cancer Centers Boulder Boulder, Colorado, United States
  • Scri Florida Cancer Specialists South Fort Myers, Florida, United States
View all 115 locations
View Trial Details
Completed

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

NCT03792256

Conditions
Acute Leukemia, Disease Attributes, Hematologic Diseases, +22 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Loma Linda University Medical Center Loma Linda, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
View all 19 locations
View Trial Details
Completed

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

NCT05227144

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • James R. Berenson, MD, Inc. West Hollywood, California, United States
  • Northside Hospital Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinical Rochester Rochester, Minnesota, United States
View Trial Details
Completed

Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices

NCT03808818

Conditions
Behavior, Carcinoma, Carcinoma in Situ, +13 more
Locations
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Katmai Oncology Group Anchorage, Alaska, United States
  • Northside Hospital Atlanta, Georgia, United States
  • Augusta University Medical Center Augusta, Georgia, United States
View all 42 locations
View Trial Details
Completed

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

NCT03268382

Conditions
Adnexal Diseases, Disease Attributes, Endocrine Gland Neoplasms, +17 more
Locations
  • Medische oncologie, Universitair Ziekenhuis Gent Ghent, Belgium
  • Leuven University Hospitals Leuven, Belgium
  • Centre Hospitalier Universitaire de Liège Liège, Belgium
  • Institut Català d'Oncologia, Hospital Germans Trias i Pujol Badalona, Spain
View Trial Details
Completed

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

NCT02098343

Conditions
Adnexal Diseases, Disease Attributes, Endocrine Gland Neoplasms, +17 more
Locations
  • UCLA Los Angeles, California, United States
  • University of Chicago Chicago, Illinois, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 55 locations
View Trial Details
Completed

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

NCT01828021

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +8 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Stanford University Stanford, California, United States
  • Florida Cancer Research Institute Plantation, Florida, United States
  • Indiana University Indianapolis, Indiana, United States
View Trial Details

Related conditions